statements

Shukra Pharmaceuticals Ltd.

BSE: 524632

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

31.86-0.5 (-1.42%)

24 Jul, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Shukra Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	5.34	5.66	11.85	11.20	20.49	58.83	74.57	32.59	56.73
Cost of Operating Revenue	1.69	1.95	4.48	4.24	12.01	47.15	46.54	11.12	19.29
Gross Profit	3.66	3.71	7.37	6.95	8.48	11.68	28.04	21.47	37.44
Gross Margin	68.4	65.5	62.2	62.1	41.4	19.9	37.6	65.9	66.0
Total Operating Expenses	4.47	4.97	11.78	11.23	19.26	55.31	57.22	22.86	31.43
Operating Profit	0.88	0.69	0.06	-0.03	1.22	3.53	17.35	9.72	25.30
Operating Margin	16.4	12.1	0.5	-0.3	6.0	6.0	23.3	29.8	44.6
Financing Income/(Expense) - Net	-0.04	0.00	0.00	-0.03	-0.29	-0.28	-0.29	0.88	-1.09
Profit before Taxes	0.95	0.72	0.17	0.10	1.02	4.44	19.88	13.34	28.79
Income Taxes	0.42	0.26	0.14	-0.09	0.27	0.04	1.35	3.76	6.73
Profit after Tax	0.53	0.46	0.04	0.19	0.75	4.41	18.54	9.58	22.06
PAT Margin	9.8	8.2	0.3	1.7	3.7	7.5	24.9	29.4	38.9
EPS - Basic - ex Extraordinary Items	0.02	0.02	0.00	0.01	0.02	0.66	0.42	0.22	0.50
EPS - Diluted - ex Extraordinary Items	0.02	0.02	0.00	0.01	0.02	0.66	0.42	0.22	0.50
EBIT	0.88	0.69	0.06	-0.03	1.22	3.53	17.35	9.72	25.30
EBITDA	1.62	1.65	1.54	1.44	2.89	5.36	19.40	12.73	28.74
EBITDA Margin	30.2	29.1	13.0	12.9	14.1	9.1	26.0	39.1	50.7

Balance Sheet

Abridged

Understanding Balance Sheet

Shukra Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	8.27	11.07	14.45	16.06	15.67	53.07	56.23	65.43	83.81
Long-Term Investments	0.05	0.05	0.05	0.19	0.20	-	-	-	-
Property Plant & Equipment - Net	15.78	17.27	19.04	19.35	19.24	21.89	21.60	21.34	33.63
Total Non-Current Assets	15.83	17.32	19.09	19.55	19.45	21.89	21.60	21.34	33.63
Total Assets	24.10	28.39	33.55	35.61	35.11	74.97	77.84	86.77	117.44
Total Current Liabilities	2.66	4.00	6.99	7.03	12.38	42.51	14.15	17.28	23.09
Long Term Debt	3.58	6.06	8.05	9.77	3.13	3.77	2.66	3.11	3.19
Total Non-Current Liabilities	6.43	9.02	11.15	12.97	6.39	7.16	6.04	6.65	4.50
Total Liabilities	9.09	13.01	18.13	20.01	18.76	49.67	20.20	23.93	27.59
Total Shareholders' Equity	15.01	15.38	15.41	15.60	16.35	25.30	57.64	62.84	89.85
Total Equity	15.01	15.38	15.41	15.60	16.35	25.30	57.64	62.84	89.85
Total Liabilities & Equity	24.10	28.39	33.55	35.61	35.11	74.97	77.84	86.77	117.44

Cash Flow

Abridged

Understanding Cash Flow Statement

Shukra Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1.57	1.54	1.75	1.57	2.24	5.60	21.08	12.58	30.61
Working Capital - Increase/(Decrease)	-0.74	-1.28	-0.51	-1.00	5.50	-2.62	-26.01	-3.78	-26.05
Net CF from Operating Activities	0.84	0.26	1.24	0.57	7.74	2.98	-4.92	8.80	4.55
Capital Expenditures - Net	4.75	2.45	3.11	1.79	1.55	4.49	1.76	2.74	15.73
Net CF from Investing Activities	-4.75	-2.45	-3.11	-1.93	-1.56	-4.49	-1.76	-2.74	-15.73
Dividends Paid - Cash - Total	0.09	0.09	-	-	-	0.07	0.07	4.38	0.44
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	4.63	13.87	-	5.39
Debt - LT & ST - Issuance/(Retirement) - Total	3.55	2.47	1.99	1.74	-6.39	0.64	-1.11	0.46	0.08
Net Cash Flow from Financing Activities	3.45	2.38	1.99	1.74	-6.39	5.20	12.69	-3.92	5.03
Free Cash Flow to Equity	-0.36	0.28	0.12	0.52	-0.21	-0.87	-7.79	6.52	-11.10
Free Operating CF net dividend	-4.00	-2.28	-1.98	-1.22	6.19	-1.59	-6.75	1.68	-11.61
Free Operating CF	-3.91	-2.19	-1.98	-1.22	6.19	-1.51	-6.68	6.06	-11.18

Business Segment Analysis

FY End:

Mar 25

Shukra Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 2.74 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 32.59 Cr

Assets

Pharmaceuticals (100.0%)₹ 86.77 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 9.72 Cr

Regional Segment Analysis

Shukra Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Shukra Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Shukra Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2025 Mar 31

Pharmaceuticals	3

Frequently Asked Questions

What is the revenue of Shukra Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Shukra Pharmaceuticals Ltd. is ₹ 56.73 Cr, reflecting a 1-year growth of 74.08% and a 3-year CAGR of -1.21%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Shukra Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Shukra Pharmaceuticals Ltd. is ₹ 22.06 Cr, with a 3-year earnings CAGR of -8.62%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Shukra Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Shukra Pharmaceuticals Ltd. is approximately ₹ 25.30 Cr (based on an operating margin of 44.59%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Shukra Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Shukra Pharmaceuticals Ltd. is 0.50. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Shukra Pharmaceuticals Ltd.?

The debt-to-equity ratio of Shukra Pharmaceuticals Ltd. stands at 0.06. The interest coverage ratio is 23.14x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Shukra Pharmaceuticals Ltd.?

The estimated book value per share of Shukra Pharmaceuticals Ltd. is 2.04 (derived from a P/B ratio of 15.59 and market price of ₹ 31.86), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Shukra Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Shukra Pharmaceuticals Ltd. is ₹ 4.55 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Shukra Pharmaceuticals Ltd. report consolidated or standalone financials?

Shukra Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.